|Description||Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret.|
|Related CAS||1058156-90-3 (free base)|
|Synonyms||1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]cyclopropanamine Hydrochloride (1:2); AL3818 Dihydrochloride; Anlotinib 2HCl; AL3818 2HCl|
Gandotinib is a potent and selective JAK inhibitor, which effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55...
SU5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor.
BIBF 1120 esylate
Nintedanib esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
Potent and selective inhibitor of VEGFR2 (IC50: 2 nM for VEGFR2 vs >50 mM for VEGFR1 respectively)
AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 an...
Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 1...
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...
BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...